- Home
- QQQX vs AUPH Comparison
QQQX vs AUPH Comparison
Compare QQQX & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QQQX
- AUPH
- Stock Information
- Founded
- QQQX 2007
- AUPH 1993
- Country
- QQQX United States
- AUPH Canada
- Employees
- QQQX N/A
- AUPH N/A
- Industry
- QQQX Finance Companies
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- QQQX Finance
- AUPH Health Care
- Exchange
- QQQX Nasdaq
- AUPH Nasdaq
- Market Cap
- QQQX 1.2B
- AUPH 999.8M
- IPO Year
- QQQX N/A
- AUPH 1999
- Fundamental
- Price
- QQQX $25.38
- AUPH $7.96
- Analyst Decision
- QQQX
- AUPH Strong Buy
- Analyst Count
- QQQX 0
- AUPH 2
- Target Price
- QQQX N/A
- AUPH $11.50
- AVG Volume (30 Days)
- QQQX 127.6K
- AUPH 1.3M
- Earning Date
- QQQX 01-01-0001
- AUPH 07-31-2025
- Dividend Yield
- QQQX 7.03%
- AUPH N/A
- EPS Growth
- QQQX N/A
- AUPH N/A
- EPS
- QQQX N/A
- AUPH 0.27
- Revenue
- QQQX N/A
- AUPH $247,295,000.00
- Revenue This Year
- QQQX N/A
- AUPH $12.15
- Revenue Next Year
- QQQX N/A
- AUPH $18.31
- P/E Ratio
- QQQX N/A
- AUPH $29.47
- Revenue Growth
- QQQX N/A
- AUPH 29.20
- 52 Week Low
- QQQX $20.27
- AUPH $5.15
- 52 Week High
- QQQX $25.99
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- QQQX 64.63
- AUPH 46.96
- Support Level
- QQQX $24.83
- AUPH $7.77
- Resistance Level
- QQQX $25.32
- AUPH $8.58
- Average True Range (ATR)
- QQQX 0.26
- AUPH 0.31
- MACD
- QQQX 0.01
- AUPH -0.03
- Stochastic Oscillator
- QQQX 97.80
- AUPH 43.89
About QQQX Nuveen NASDAQ 100 Dynamic Overwrite Fund Shares of Beneficial Interest
Nuveen NASDAQ 100 Dynamic Overwrite Fund is a closed-end management investment company. Its investment objective is to seek an attractive total return with less volatility than the Nasdaq 100 Index. Under normal circumstances, the Fund will invest at least 80% of its Assets in an equity portfolio made up of securities comprising the Nasdaq 100 Index (or securities that have economic characteristics that are similar to those securities comprising the Nasdaq 100 Index) that seeks to substantially replicate price movements of the Nasdaq 100 Index and is designed to support the Fund's option strategy.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.